Komori
Earnings7775DAIKEN MEDICAL CO.,LTD.Electrical Equipment and Precision Instruments

Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)

For the fiscal year ending March 2026, net sales increased 3.4% on strong sales of the Company's core products, while operating profit decreased 15.5% due to higher material costs, personnel expenses and research and development expenses. For the fiscal year ending March 2027, net sales are expected to increase, but operating profit is projected to decrease 34.3% due to upfront investments and other factors.

Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
15.5
% (year-on-year decline in operating income)
Wording
Conditional
How definitive the wording is.

Results for this period

Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAP
Net Sales10,290¥ millionYear on year +3.4%Progress 98.0%
Operating profit1,277¥ millionYear on year -15.5%Progress 152.0%
Ordinary income1,274¥ millionYear on year -15.6%Progress 154.4%
Net income attributable to owners of the parent922¥ millionYear on year -15.9%Progress 156.3%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥32.12
Operating Margin12.4%
Financial position at period-end
Total assets11,366¥ million
of which net assets 7,777 ¥ millionEquity ratio 68.2%vs. prior year-end +1.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+567
Investment-330
Financials-455
Net change-218

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥2,778 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,500 million (YoY +2.0%)
Operating profit¥840 million (YoY -34.3%)
Ordinary income¥825 million (YoY -35.3%)
Net income¥590 million (YoY -36.1%)
Annual Dividend Forecast¥23 per share → ¥20 per share(-13.0%)
Payout ratioCurrent fiscal year 62.3% / Next-year forecast 97.4%
Shareholder Return PolicyBasic policy of returning at least 60% of profit through dividends
Factors Behind Changes in Business Performance

The main factor behind the increase in net sales was strong sales of Fitfix and Cudeck Amy PCA products. The main factors behind the decrease in operating profit were higher material costs and increases in personnel expenses and research and development expenses.

Disclosure regarding the going concern assumption

No applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares ¥404 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥28,699 thousand
Depreciation and amortization¥258 million
Orders received and order backlogNot applicable (make-to-stock production)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (no target participants specified)
Issued Shares at Period-End31,840,000
Treasury Shares at Period-End3,111,563
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 April 2025–31 March 2026
Net Sales¥10,290 million (YoY +3.4%)
Operating profit¥1,277 million (YoY -15.5%)
Ordinary income¥1,274 million (YoY -15.6%)
Profit attributable to owners of the parent¥922 million (YoY -15.9%)
Net income per share¥32.12
Operating Margin12.4%
Equity ratioEnd of the current fiscal period 68.2% / End of previous period 66.9%
Total assets¥11,366 million
Net assets¥7,777 million
Cash flows from operating activities¥567 million
Cash flows from investing activities¥-330 million
Cash flows from financing activities¥-455 million
Cash and cash equivalents at end of period¥2,778 million
Full-year earnings forecastNet Sales ¥10,500 million (YoY +2.0%) / Operating profit ¥840 million (YoY -34.3%) / Ordinary income ¥825 million (YoY -35.3%) / Net income ¥590 million (YoY -36.1%)
Annual Dividend Forecast¥23 per share → ¥20 per share(-13.0%)
Payout ratioCurrent fiscal year 62.3% / Next-year forecast 97.4%
Shareholder Return PolicyBasic policy of returning at least 60% of profit through dividends
Orders received and order backlogNot applicable (make-to-stock production)
Depreciation and amortization¥258 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares ¥404 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥28,699 thousand
Disclosure regarding the going concern assumptionNo applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsNo applicable matters.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (no target participants specified)
Issued Shares at Period-End31,840,000
Treasury Shares at Period-End3,111,563
Factors Behind Changes in Business PerformanceThe main factor behind the increase in net sales was strong sales of Fitfix and Cudeck Amy PCA products. The main factors behind the decrease in operating profit were higher material costs and increases in personnel expenses and research and development expenses.
Items this document does not state (6)
Revision to Earnings ForecastSegment revenueSegment profitRegional salesImpairment lossChanges in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

During the fiscal year, sales of Fitfix and Cudeck Amy PCA products were strong, while operating profit declined due to higher material costs and increases in personnel expenses and research and development expenses. For the next fiscal year, the Company expects upfront investments in response to higher raw material and procurement prices, supply chain upgrades, workforce expansion and wage increases, research and development, and expenses associated with its expansion into Europe.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated) | DAIKEN MEDICAL CO.,LTD. (7775) timely disclosure | Komori